These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 29188727)

  • 1. The optimal treatment of metastatic hormone-naive prostate cancer: abiraterone acetate or docetaxel?
    Aoun F; El Rassy E; Sleilaty G; Assi T; Bakouny Z; Kattan J
    Future Oncol; 2017 Dec; 13(30):2785-2790. PubMed ID: 29188727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Counterpoint: Chemotherapy vs Abiraterone for the Initial Management of Metastatic Prostate Cancer: The Case for Abiraterone.
    Jones RJ
    Oncology (Williston Park); 2018 May; 32(5):223, 226-7, 247. PubMed ID: 29847852
    [No Abstract]   [Full Text] [Related]  

  • 3. Point: Chemotherapy vs Abiraterone for the Initial Management of Metastatic Prostate Cancer: The Case for Chemotherapy.
    Isaacsson Velho P; Eisenberger MA
    Oncology (Williston Park); 2018 May; 32(5):223-6. PubMed ID: 29847851
    [No Abstract]   [Full Text] [Related]  

  • 4. Abiraterone acetate and its use in the treatment of metastatic prostate cancer: a review.
    Caffo O; Veccia A; Kinspergher S; Maines F
    Future Oncol; 2018 Feb; 14(5):431-442. PubMed ID: 29350549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study.
    Suzuki H; Shin T; Fukasawa S; Hashine K; Kitani S; Ohtake N; Shibayama K; Tran N; Mundle S; Fizazi K; Matsubara N
    Jpn J Clin Oncol; 2020 Jul; 50(7):810-820. PubMed ID: 32188988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis.
    Feyerabend S; Saad F; Li T; Ito T; Diels J; Van Sanden S; De Porre P; Roiz J; Abogunrin S; Koufopoulou M; Fizazi K
    Eur J Cancer; 2018 Nov; 103():78-87. PubMed ID: 30218976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.
    Saad F; Shore N; Van Poppel H; Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Griffin TA; De Porre P; Londhe A; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ
    Eur Urol; 2015 Oct; 68(4):570-7. PubMed ID: 25985882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis.
    Wallis CJD; Klaassen Z; Bhindi B; Goldberg H; Chandrasekar T; Farrell AM; Boorjian SA; Kulkarni GS; Karnes RJ; Satkunasivam R
    Eur Urol; 2018 Jun; 73(6):834-844. PubMed ID: 29037513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abiraterone Acetate: A Review in Metastatic Castration-Resistant Prostrate Cancer.
    Scott LJ
    Drugs; 2017 Sep; 77(14):1565-1576. PubMed ID: 28819727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Kearns B; Pandor A; Stevenson M; Hamilton J; Chambers D; Clowes M; Graham J; Kumar MS
    Pharmacoeconomics; 2017 Apr; 35(4):415-424. PubMed ID: 27770303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis.
    Vale CL; Fisher DJ; White IR; Carpenter JR; Burdett S; Clarke NW; Fizazi K; Gravis G; James ND; Mason MD; Parmar MKB; Rydzewska LH; Sweeney CJ; Spears MR; Sydes MR; Tierney JF
    Ann Oncol; 2018 May; 29(5):1249-1257. PubMed ID: 29788164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abiraterone acetate/androgen deprivation therapy combination versus docetaxel/androgen deprivation therapy combination in advanced hormone-sensitive prostate cancer: a network meta-analysis on safety and efficacy.
    Kassem L; Shohdy KS; Abdel-Rahman O
    Curr Med Res Opin; 2018 May; 34(5):903-910. PubMed ID: 29490505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of chemotherapy in the treatment of metastatic castration-resistant prostate cancer patients who have progressed after abiraterone acetate.
    Petrioli R; Francini E; Laera L; Fiaschi AI; Ponchietti R; Roviello G
    Cancer Chemother Pharmacol; 2015 Sep; 76(3):439-45. PubMed ID: 26082421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Abiraterone acetate (AA): current guidelines of prescription of abiraterone].
    Boissier E; Loriot Y; Vignot S; Massard C
    Bull Cancer; 2014 Apr; 101(4):388-93. PubMed ID: 24793632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of abiraterone acetate on circulating neuromediators in chemotherapy-naïve castration-resistant prostate cancer.
    von Hardenberg J; Schwartz M; Werner T; Fuxius S; Müller M; Bolenz C; Weiß C; Heinrich E
    Prostate; 2016 May; 76(7):613-9. PubMed ID: 26779767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of pretreatment anemia on upfront abiraterone acetate therapy for metastatic hormone-sensitive prostate cancer: a multicenter retrospective study.
    Okamoto T; Noro D; Hatakeyama S; Narita S; Mitsuzuka K; Sakurai T; Kawamura S; Hoshi S; Shimoda J; Tanaka T; Kawaguchi T; Ishidoya S; Ito A; Tsuchiya N; Habuchi T; Ohyama C
    BMC Cancer; 2021 May; 21(1):605. PubMed ID: 34034691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Maximal androgen deprivation with abiraterone acetate in hormone sensitive prostate cancer.].
    Rodríguez Antolín A; Romero Otero J; Duarte Ojeda J; García González L; Sopeña Sutil R; González Padilla D; García Rojo E; Justo Quintas J; Miñana López B
    Arch Esp Urol; 2018 Mar; 71(3):267-275. PubMed ID: 29633947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abiraterone is effective and should be considered for the treatment of metastatic castrate-naïve prostate cancer.
    Elkon JM; Millett RL; Millado KF; Lin J
    Expert Opin Pharmacother; 2018 Apr; 19(5):507-509. PubMed ID: 29494266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abiraterone acetate in the treatment of prostate cancer.
    Thakur A; Roy A; Ghosh A; Chhabra M; Banerjee S
    Biomed Pharmacother; 2018 May; 101():211-218. PubMed ID: 29494958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A drug safety evaluation of abiraterone acetate in the treatment of prostate cancer.
    Castellan P; Castellucci R; Marchioni M; De Nunzio C; Tema G; Primiceri G; Schips L; Cindolo L
    Expert Opin Drug Saf; 2019 Sep; 18(9):759-767. PubMed ID: 31353982
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.